Background: Treatment of pulmonary metastasis from urothelial cell carcinoma has been mostly palliative chemotherapy and the role of pulmonary metastasectomy has not been investigated much. Materials and Methods: This study is a retrospective interim review of pulmonary metastasectomy from urothelial carcinoma at single institution between 1998 and 2010. Overall 16 patients underwent pulmonary metastasectomies. Results: There was no postoperative complication or hospital mortality. Mean hospital stay was 6 days. Overall and disease-free 5-year survival were 65.3% and 37.5%, respectively. Conclusion: In selected patients with pulmonary metastasis from urothelial carcinoma, surgical treatment is feasible and could contribute to long-term survival in selected patients.
INTRODUCTION
Although systemic chemotherapy is the mainstay of treatment for distant metastasis of cancer, there are several cancers known to have survival benefit from pulmonary metastasectomy, which include colorectal carcinoma, renal cell carcinoma, and osteosarcoma. But in relatively chemosensitive malignancies, role of metastasectomy is not well established [1] .
Systemic chemotherapy remains the standard treatment for metastatic urothelial cancer since cisplatin-based combination chemotherapy introduced in the 1980s. Despite relatively high response rate of chemotherapy (range, 50% to 70%), patients frequently experiences recurrence and have poor prognosis [2] . Surgical resections of lung metastases from urothelial carcinoma are not common, and there are limited data for role of metastasectomy on long-term survival.
In this study, we retrospectively reviewed our experience to identify the feasibility and benefits of pulmonary metastsectomy from urothelial cancer.
MATERIALS AND METHODS
Between 1998 and 2010, 16 patients of urothelial carcinoma with lung metastasis underwent metastasectomy at Samsung Medical Center. Eligible criteria for surgical resection are as follows: 1) the pulmonary lesion must be completely resectable; 2) metastasis was limited to the lung; 3) primary tumor had been or could be completely controlled; and 4) patient was medically operable and had sufficient expected pulmonary reserve after resection [3] .
After surgery for primary tumor, adjuvant chemotherapy [4] . Regimens for adjuvant chemotherapy were generally 3 cycles of gemcitabine and cisplatin (GP). Palliative regimens were mostly 4 to 6 cycles of GP, but sometimes methotrexate, vinblastine, doxorubicin, and cisplatin were used. Same policies and regimen were used after pulmonary metastasectomy, considering patients condition.
After initial surgery for primary tumor, chest computed to- This study was reviewed and approved by institutional review boards in Samsung Medical Center.
RESULTS

Patient demographics and clinicopathologic characteristics
were illustrated in Table 1 . Complete resection was achieved in all patients. Sublobar resection was performed in 10 patients (8 wedge resections and 2 segmentectomies). Lobectomy was performed in 6 patients. In 3 patients, intraoperative frozen section of nodule could not differentiate it from primary lung cancer due to very poor differentiation of tumor, and therefore, lobectomy was performed with mediastinal lymph node dissection. In the other 3 patients, nodule was centrally located and sublobar resection was not possible.
The median hospital stay was 5 days (range, 2 to 10 days).
There were neither postoperative complications nor hospital mortality.
The 5-year overall survival and disease free survival were 65.3% and 37.5%, respectively ( group and the number of chemotherapy cycle, sites of metastasis, and resection of metastasis were independent predictors on survival [7] . Recently Matsuguma et al. [8] reviewed 32 patients with urothelial cancer who underwent pulmonary metastasectomy for curative intent. They reported 5-year overall survival rate of 50% and size of metastasis greater than 3 cm was a significant poor prognostic factor [8] . In 2010,
Kanzaki et al. [1] reviewed data from 18 patients who underwent pulmonary metastasectomy from transitional cell carcinoma and reported cumulative 3 and 5-year survival rate of 59.8% and 46.5%. They also found solitary metastasis is associated with good prognosis [1] . In our series, we also observed favorable survival in after metastasectomy from ur-− 245 − othelical cell carcinoma. Overall and disease-free 5-year survival were 65.3% and 37.5%, respectively. We also observed favorable survival after repeated pulmonary metastasectomy.
Those 5 patients in our series had recurrent pulmonary metastasis but not in other organs. All of them underwent repeated resection and two of them underwent third resection for recurrent disease. All these patients are alive until now without recurrence.
Our study has some obvious limitations. First, just as mentioned above, patient population is too small. We could have only 16 cases of pulmonary metastasectomy for 12-years period. Second, it was very difficult to compare the results of surgery with those of non-surgical treatment because of differences in patient characteristics between the two groups.
Patients without metastasectomy usually had much advanced disease with multiple metastases to the lung or various organs, or their physical performance or pulmonary reserves are not sufficient for additional surgery. Therefore, we could not find comparable groups without metastasectomy to those with it. Third, many patients in Samsung Medical Center who could have been potentially candidates of pulmonary metastasectomy might not have referred to surgery due to lack of agreements for pulmonary surveillance and treatment strategy for pulmonary metastasis after surgery of urothelial cell carcinoma, and these can lead to selection bias.
CONCLUSION
Although there is still limitation, pulmonary metastasectomy can be applied in patients who have pulmonary metastasis from urothelial carcinoma with favorable outcomes.
